Guardant Health Leads the Way in Blood-Based Single Cancer Screening
Guardant Health is a leader in liquid biopsy. It has market-leading platforms in tumor genomic profiling, molecular residual disease, or MRD, testing, and colorectal cancer screening. Although these are promising markets with multibillion-dollar revenue potential, it is still the early days, with considerable uncertainty about payer coverage and guideline inclusion. We do not expect the company to generate positive cash flows until 2028.
United States